Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Accumulated Expenses (2016 - 2025)

Capricor Therapeutics has reported Accumulated Expenses over the past 9 years, most recently at $6.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $6.7 million for Q4 2025, up 162.9% from a year ago — trailing twelve months through Dec 2025 was $6.7 million (up 162.9% YoY), and the annual figure for FY2025 was $6.7 million, up 162.9%.
  • Accumulated Expenses for Q4 2025 was $6.7 million at Capricor Therapeutics, down from $9.9 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CAPR hit a ceiling of $9.9 million in Q3 2025 and a floor of $1.9 million in Q1 2025.